Results filed 2 November 2026 · Market cap ₹11,664 crore · PE 30.9
GrowthTranscript read
Revenue
+31.9%
on a year ago
EBITDA
+106.1%
on a year ago
Profit to shareholders
+176.7%
on a year ago
EBITDA margin
14.5%
−0.5 pts on last quarter
Akums Drugs delivered strong Q2 FY27 performance with revenue rising 31.9% YoY to INR 1,342 crore and EBITDA more than doubling to INR 195 crore, driven by >20% volume growth in core CDMO operations. Domestic branded formulation EBITDA fell 8.9% YoY due to front-loaded sales force investments, while the API business remained loss-making with an EBITDA deficit of INR 5.7 crore. Balance sheet cash and equivalents reached INR 1,680 crore supported by customer advances, with commercial revenue from the Zambia and European CDMO projects scheduled to commence in FY28.
Akums Drugs and Pharmaceuticals Limited, Q2 FY27₹ crore, consolidated
Q2 FY27
Q1 FY27
vs previous quarter
Q2 FY26
vs a year ago
Revenue
1,342
1,167
+15.1%
1,018
+31.9%
Operating profit (EBIT)
152
134
+13.4%
56.61
+167.7%
Operating margin
11.3%
11.5%
−17 bps
5.6%
+572 bps
Other income
28.91
30.38
−4.8%
32.37
−10.7%
Exceptional items
0
0
–
0
–
Profit before exceptional items and tax
155
139
+11.1%
65.67
+135.6%
Profit to shareholders
113
100
+12.8%
40.78
+176.7%
Earnings per share (₹)
7.37
6.53
+12.9%
2.66
+177.1%
Source: Akums Drugs and Pharmaceuticals Limited’s filing to NSE, 2 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Consolidated EBITDA more than doubled YoY (+106.1%) with 525 bps margin expansion to 14.5%, driven by CDMO volume growth over 20%.SourcePresentation slide 10, 12; Transcript original page 3, 5 (Sandeep Jain, Sumeet Sood)
Interest income from customer advances constitutes nearly 20% of PBT, with revenue recognition from the $100M European advance deferred until dossier approvals and FY28 supplies.SourceTranscript original page 8-9 (Abhi Jain, Sumeet Sood)
Management stated no provision is required for the NPPA Paragraph 15(8BC) show-cause notice as Akums operates as a job-worker with contractually indemnified liabilities.SourceTranscript original page 9 (Sumeet Sood)
Book USD 25 million revenue in Q1 FY28 post Q4 FY27 shipping dispatch
Q1 FY28
Tailwinds
Strong CDMO volume growth exceeding 20% YoY for four consecutive quarters driven by existing and new customers across prescription, private label, and regional markets.SourceTranscript original pages 3, 7, 11, 13 (Sandeep Jain, Sahil Maheshwari)
Operating leverage significantly reduced employee and other expenses as a percentage of sales, lifting EBITDA margin by 525 bps YoY to 14.5%.SourcePresentation slide 12, 16; Transcript original page 5 (Sumeet Sood)
International branded formulation business expanded rapidly, with revenue up 95.2% YoY to INR 44 crore and EBITDA up 80.5% YoY to INR 9.9 crore.SourcePresentation slide 18; Transcript original page 5 (Sumeet Sood)
Trade generics segment sustained profitability for the third consecutive quarter with INR 1.2 crore EBITDA, following deliberate business pruning.SourcePresentation slide 18; Transcript original pages 4, 5, 15 (Sumeet Sood, Sahil Maheshwari)
Headwinds
API segment revenue fell 35.3% YoY to INR 29 crore and generated an EBITDA loss of INR 5.7 crore (worsening sequentially from INR 3.9 crore loss in Q1 FY27).SourcePresentation slide 18; Transcript original page 5 (Sumeet Sood)
Domestic branded formulations EBITDA declined 8.9% YoY to INR 24 crore (margin down from 21.6% to 18.2%) due to the upfront cost of adding 200 field force personnel, which depressed PCPM to 2.5.SourcePresentation slide 18; Transcript original pages 5, 12, 14 (Sumeet Sood, Sahil Maheshwari)
Input material cost volatility across basic chemicals, KSMs, husk, and solvents pushed API basket purchase prices up 5% to 7% YoY and 2% to 3% QoQ.SourceTranscript original page 13 (Sahil Maheshwari)
New businesses and products
capacity expansion · Phase 1 under commissioning, expected to operationalize within 3 to 4 months (Q1 FY28)
New oral solids manufacturing facility at Baddi (Phase 1 and 2)
Expected benefit
Phase 1 adds 6 billion oral solid units, Phase 2 adds another 6 billion units (total 12 billion); facility expected to contribute 10% to 15% of CDMO business in 3 years with ~3x gross block turnover
Risks
Ramp-up timeline and capital deployment
Timeline
Phase 1 operational by Q1 FY28; complete in 3 phases over 3 years
Investment
INR 43 crore invested in H1 FY27; total capex not specified
partnership · Purchase orders received; Indian manufacturing underway; technical discussions for Zambia plant complete
Zambia Government joint venture and supply contract
Expected benefit
USD 25 million revenue from initial supply tranche at margins slightly higher than base CDMO, followed by a potential second USD 25 million tranche; local plant operational in 2029
Risks
Prolonged shipping lead times of 100 to 120 days from Haridwar to Lusaka; political/election cycle lead times
Timeline
Supplies dispatched Q4 FY27, revenue recognition in Q1 FY28; local plant operational in 2029
SourceTranscript original pages 4, 6, 10-11 (Sandeep Jain, Sahil Maheshwari)
new geography · Dossier filed; 2 products approved, 8 filed, over 30 in R&D; 2 facilities EU-GMP certified
European CDMO regulated market expansion
Expected benefit
Higher margin CDMO revenue; supplies backed by customer advance
Risks
Regulatory approval lead times (estimated at 1-2 quarters)
Timeline
Dossier approval expected in 1-2 quarters; commercial supplies commencing in FY28
Investment
Funded in part by USD 100 million advance; R&D spend >3% of CDMO revenue
High proportion of pre-tax earnings derived from interest on advances: Other income stood at INR 29 crore out of INR 155 crore PBT (~18.7%), largely generated from parked customer advance deposits.SourcePresentation slide 12; Transcript original page 8 (Abhi Jain, Sumeet Sood)
Outstanding NPPA Paragraph 15(8BC) show-cause notice for FY19-FY25 carrying potential overcharging claims, for which zero balance sheet provision has been made based on job-work indemnity clauses.SourceTranscript original page 9 (Abhi Jain, Sumeet Sood)
How the call went
The call offered useful color on international contracts, R&D progress, and manufacturing capacities, but management refrained from giving formal financial guidance or quantifying the full Baddi capex program.
Specific or vague
Management provided detailed divisional metrics (1,600 MRs, 450 line managers, 375 R&D scientists, 6B tablet Phase 1 capacity, PCPM of 2.5), but declined to share overall top-line guidance or absolute capex numbers for the Baddi facility.
Candour
Management was forthright regarding the EBITDA drag caused by new MR hiring and conceded ongoing quarterly losses in the API business (~INR 5.7 cr loss), while clarifying that Oriflame's current PAT contribution is negligible.
The hard questions
Directly addressed queries on the NPPA show-cause notice and the P&L accounting of the USD 100 million advance, but gave generic turnover rules of thumb instead of specific capex quantum for Baddi.
What analysts pressed on
Revenue and profit recognition mechanics for the USD 100M European advance and the sustainability of interest income (20% of PBT)
Financial exposure and balance sheet provisioning regarding the NPPA Paragraph 15(8BC) notice
Delivery schedule and revenue recognition timelines for the Zambia JV contract
Underperformance and margin compression in domestic branded formulations vs IPM
Timeline and roadmap to curtail persistent EBITDA losses in the API division
Answers that sidestepped
Avoided providing total capex budget for the new Baddi facility, stating only that oral solids generate a 3x asset turnover on gross block
Declined to offer consolidated top-line growth guidance for FY27
Numbers against the story
Management's narrative emphasized exceptional consolidated EBITDA expansion (+106.1% YoY) and volume strength (+20% YoY in CDMO), which is fully supported by reported figures. However, the domestic branded segment suffered an 8.9% YoY EBITDA decline due to hiring costs despite positive narrative on therapy presence, and the API division saw a 35.3% YoY revenue slump with continuing quarterly EBITDA losses (-INR 5.7 cr).
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.